2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor

P2Y Receptor

P2Y Receptor

Related Products

PDF 0.7 MB

P2Y receptors are a class of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides (ATP, UTP, and UDP). There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain.

The P2Y family can be further divided into a subfamily of five P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs (“P2Y1-like”) that stimulate phospholipase C (PLC) through Gq protein and a second subfamily of P2Y12, P2Y13, and P2Y14Rs (“P2Y12-like”) that inhibit adenylate cyclase through Gi protein. Other effector pathways have been documented, such as coupling of the P2Y11R to Gs as well as to Gq in some cells to induce stimulation of cyclic AMP production.

P2Y Receptor Isoform Specific Products:

P2Y Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-164090
    Adenosine 3'-phosphate 5'-phosphosulfate
    		Antagonist
    Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
    Adenosine 3'-phosphate 5'-phosphosulfate
  • HY-134369
    Ap4C tetrasodium
    Ap4C tetrasodium is a dinucleoside polyphosphate containing purine and pyrimidine base moieties. Ap4C tetrasodium acts as a signaling molecule by binding to specific P2Y receptors, activating P2Y2 and P2Y4 receptors in platelets, leading to platelet aggregation and other cellular responses. Ap4C tetrasodium can be used for research in inflammation and blood coagulation.
    Ap4C tetrasodium
  • HY-163645
    P2Y12 antagonist 1
    		Antagonist
    P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent.
    P2Y12 antagonist 1
  • HY-10064R
    Ticagrelor (Standard)
    		Antagonist
    Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
    Ticagrelor (Standard)
  • HY-123202
    MRS2603
    		Antagonist
    MRS2603 is a pyridoxal derivative. MRS2603 antagonized both P2Y1 and P2Y13 receptors.
    MRS2603
  • HY-15283R
    Clopidogrel (Standard)
    		Inhibitor
    Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Clopidogrel (Standard)
  • HY-119145
    MRS2496
    		Antagonist
    MRS2496 is a selective P2Y1 receptor antagonist with an IC50 value of 1.5 μM, exhibiting antiplatelet aggregation activity. MRS2496 can be used in the research of antiplatelet aggregation and blood-related diseases.
    MRS2496
  • HY-110043
    (±)-Clopidogrel hydrochloride
    		Control
    (±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors.
    (±)-Clopidogrel hydrochloride
  • HY-10064S1
    Ticagrelor-d4
    		Antagonist
    Ticagrelor-d4 (AZD6140-d4) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
    Ticagrelor-d<sub>4</sub>
  • HY-W419570
    (Rac)-BX 048
    		Antagonist
    (Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC50 of 15 μM).
    (Rac)-BX 048
  • HY-11024
    ADP receptor-IN-1
    		Inhibitor
    ADP receptor-IN-1 (compound 21) is a platelet ADP receptor inhibitor. ADP receptor-IN-1 shows both IC50 values <10 μM at a platelet ADP receptor binding assay and aggregation using a platelet-rich plasma assay.
    ADP receptor-IN-1
  • HY-148596
    UDP-GlcNAc
    		Agonist
    UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc is a nucleotide sugar used by Glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is the sugar nucleotide donor for the synthesis of O-GlcNAc modified proteins. UDP-GlcNAc also acts as a full agonist of the P2Y14 receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections.
    UDP-GlcNAc
  • HY-137602
    P1,P2-Diuridine-5’-diphosphate
    		Activator
    P1,P2-Diuridine-5’-diphosphate (Up2U) is a symmetrical dinucleoside polyphosphate containing two pyrimidine base moieties. P1,P2-Diuridine-5’-diphosphate is also an activator of purinergic P2Y receptor.
    P1,P2-Diuridine-5’-diphosphate
  • HY-15284B
    Prasugrel (Maleic acid)
    		Inhibitor
    Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel (Maleic acid)
  • HY-19638AR
    Cangrelor tetrasodium (Standard)
    		Antagonist
    Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
    Cangrelor tetrasodium (Standard)
  • HY-N9422
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine
    		Antagonist
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine
  • HY-15283AS
    (±)-Clopidogrel-d7 sulfate
    (±)-Clopidogrel-d7 (sulfate) is the deuterium labeled (±)-Clopidogrel sulfate.
    (±)-Clopidogrel-d<sub>7</sub> sulfate
  • HY-137608
    Uridine 5'-O-thiodiphosphate
    		Agonist
    Uridine 5'-O-thiodiphosphate (UDP-β-S) is a P2Y6 receptor agonist with an EC50 of 25 nM. Uridine 5'-O-thiodiphosphate resists degradation by extracellular nucleotidases and stimulates the accumulation of inositol phosphates. Uridine 5'-O-thiodiphosphate stimulates contractile responses in endothelium-denuded rat mesenteric arteries. As a mitogen, Uridine 5'-O-thiodiphosphate stimulates DNA synthesis, [3H] thymidine incorporation, protein synthesis, [3H]leucine incorporation, and increases the number of vascular smooth muscle cells. Uridine 5'-O-thiodiphosphate can be used in the research of cardiovascular diseases such as atherosclerosis.
    Uridine 5'-O-thiodiphosphate
  • HY-137418
    2-MeS-ATP
    		Agonist
    2-MeS-ATP (2-Methylthio-ATP) is an analog of adenosine nucleotides and acts as a P2Y purinergic receptor agonist specific for adenosine nucleotide activation. 2-MeS-ATP is also able to inhibit the release of toxic mediators from macrophages stimulated by endotoxin (LPS). 2-MeS-ATP can be used in the study of endotoxin shock and inflammatory diseases.
    2-MeS-ATP
  • HY-N7114AR
    Chloramphenicol succinate sodium (Standard)
    		Inhibitor
    Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease.
    Chloramphenicol succinate sodium (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
P2Y Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.